Consider the following argument:
'Pharmaceutical executives contend that extending patent exclusivity periods is essential to funding high-risk biomedical research. However, public health economists observe that protracted exclusivity inflates healthcare expenditures without demonstrably increasing the rate of novel drug discovery. Although industry advocates argue that reduced patent lifespans would deter capital investment in critical therapeutic areas, comparative cross-national data demonstrate that robust public-venture funding effectively offsets private investment declines. Therefore, lengthening patent monopolies is an inefficient strategy for fostering pharmaceutical innovation.'
Which of the following correctly matches each claim from the passage with its structural role in the overall argument?
- Extending patent exclusivity periods is essential to funding high-risk biomedical research.The primary opposing position held by industry executives that the argument overall seeks to evaluate and reject.
- Protracted exclusivity inflates healthcare expenditures without demonstrably increasing the rate of novel drug discovery.Empirical evidence introduced to directly counter the necessity claim of the initial opposing stance.
- Reduced patent lifespans would deter capital investment in critical therapeutic areas.A defensive counter-claim raised by advocates to justify maintaining long patents despite cost concerns.
- Lengthening patent monopolies is an inefficient strategy for fostering pharmaceutical innovation.The main conclusion reached by the author after addressing the opposing claims and counterarguments.